US Patent
US10406108 — Thyroid hormone oral dosage forms and methods of using the same
Formulation · Assigned to Genus Lifesciences Inc · Expires 2038-03-23 · 12y remaining
Vulnerability score
50/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects novel thyroid hormone oral dosage forms and methods of making and using them.
USPTO Abstract
Novel thyroid hormone oral dosage forms and methods of making and using the thyroid hormone oral dosage forms are disclosed.
Drugs covered by this patent
- Unithroid (LEVOTHYROXINE SODIUM) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.